I-124 PET Directed Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer: the I-FIRST Study

Description: For patients with advanced thyroid cancer, tumours that no longer trap radioiodine have an extremely poor prognosis and more effective treatments are urgently required. This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life.

Dates

State ongoing
Start 2021-01-01
End 2026-01-01
Form updated 2023-03-27

Report authors

Portia Dilena (link)

Jack Nunn (link)
0000-0003-0316-3254
Checked report and added URL

Location

Australia

URL

template:str right/Ga/Show/6c463857-6f42-4bb8-ad2f-3933a356e2b0

Aims

This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life

We will also determine the affordability of bringing this therapy to the clinic

Category

research

Inputs

individual

Andrew Scott (link)

---

Task: Lead Chief Investigator
Compensation: paid

funding

(link)

---

2,708,660.70 (AUD)